РОЛЬ ГЕНА РЕЦЕПТОРА АКТИВАТОРА ПЕРОКСИСОМ ПРИ ЦУКРОВОМУ ДІАБЕТІ II ТИПУ
Ключові слова:
ген рецептора активатора пероксисом, PPARG, ЦД 2 типу, цукровий діабет, перекисне окислення ліпідів, оксидативний стрес
Анотація
Цукровий діабет [ЦД] II типу - одне з найпоширеніших захворювань, що є глобальною медичною проблемою і становить загрозу для здоров’я людства. Це обумовлено тенденцією до зростання кількості таких хворих, особливо серед людей працездатного віку (40-59 років), та наявністю чисельних ускладнень, що визначають важкість захворювання. В основі ускладнень ЦД II типу лежить гіперглікемія та перекисне окислення ліпідів, які ведуть до розвитку оксидативного стресу. Одне з провідних значень в патогенезі ЦД II типу відіграє генетична передумова. Не дивлячись на полігенну природу ЦД II типу, поліморфізм гена PPARG - основний маркер розвитку захворювання. Гомозиготи з 12Pro (PPARG) більш схильні до розвитку оксудативного стресу та судинних ускладнень ніж носії алеля Ala.
Посилання
1. Global status report on noncommunicable diseases 2014 [Yelektronniy resurs]. — 2012. — Rezhim dostupu do resursu: http://apps.who. int/iris/bitstream/ 10665/148114/1/9789241564854_eng.pdf?ua=l
2. World Health Organization. Global Health Estimates: Deaths by Cause, Age, Sex and Country, 2000 — 2012. Geneva // WHO — 2014.
3. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 203 0. // PLoS Med - 2006, -3[ll]-s. 442.
4. Diabet — informatsionnyy byulleten VOZ №312, yanvar, 2015 g. [http:// www.who.int/mediacentre/factsheets/fs312/ru/]
5. Hu FB. Globalization of Diabetes: The role of diet, lifestyle, and genes. Diabetes Care — 2011;34[6] — s. 1249-1257. [Yelektronniy resurs].— Rezhim dostupu do resursu: http://dxdoi.org/10.2337/dcll-0442
6. Mayer-Davis EJ. Type 2 diabetes in youth: epidemiology and current research toward prevention and treatment //J. Am. Diet Assoc. — 2008. — Vol. 108, № 4 [Suppl 1]. - S.S45-S51.
7. Zhurakivska O.Ya., Titik W, Zhurakivska V.M., Pertsovich V.M., Rol protsesiv perokisnogo okislennya lipidiv и rozvitku diabetichnikh mikroangiopatiy // Zdobutki klinichnoi і eksperimentalnol meditsini — 2014 — № 12-S.232
8. Osnovni pokazniki diyalnosti endokrinologichnol sluzhbi Ukralni za 2003 rik [dovidnik], — Kilv, 2004. — s. 23.
9. Dovidnik osnovnikh pokaznikiv diyalnosti endokrinologichnol sluzhbi Ukralni za 2003 rik // Yendokrinologiya. — 2014. — T. 19, №1, dodatok 1. — s. 40
10. Tkachenko VI., k. med. n., dotsent, Analiz poshirenosti ta zakhvoryuvanosti na TsD sered naselennya svitu ta Ukralni za 2003—2013 rr. //Liki Ukralni -2014- №4 [21] - s. 55-59.
11. ZimmetP., Abstract Book The 2nd Xenical Event Monte Carlo, March 14— 16, 2003.
12. Butrova S.A., Ot epidemii ozhireniya k epidemii sakharnogo diabeta // Mezhdunarodnyy endokrinologicheskiy zhurnal — 2013 - № 2[50] — s. 19-23, ISSN 2224-0721.
13. Suplotova L.A., 2 Belchikova L.N., 2 Rozhnova N. A. Epidemiologicheskie aspekty sakharnogo diabeta 2 tipa s manifestatsiey zabolevaniya v molodom vozraste Epidemiologiya // Sakharnyy diabet. - 2012;[1]: - s. 11—13.
14. ZimmetP, Alberti K. et al. //Nature. - 2001. — 414. S. 782-7.
15. Dedova I.I., Algoritmy spetsializirovannoy meditsinskoy pomoshchi bol- nym sakharnym diabetom. [6-у vypusk]. //Sakharnyy diabet. —2013 - [Is] — s.1—120.
16. Baranov VS, Glotov AS, Ivashchenko ТЕ. Geneticheskiy pasport — osnova individualnoy і prediktivnoy meditsiny. // Sankt-Peterburg: Izdatelstvo N-L; - 2009.
17. Klyueva S.K, Multifaktorialnye zabolevaniya. // SPb.: SPb. МАРО - 2002. — s. 144
18. Dedov I.I., Smirnova O.M., Kononenko I.V.,Znachenie rezultatov polnogenomnykh issledovaniy dlya pervichnoy profilaktiki sakharnogo diabeta 2 tipa і ego oslozhneniy. Personalizirovannyy podkhod // Sakharnyy diabet. - 2014;[2] - s. 10-19
19. Bondar I.A., Shabelnikova O.Yu. Geneticheskie osnovy sakharnogo diabeta 2 tipa //Sakharnyy diabet. - 2013;[4] — s.11—16
20. Kobberling J, ТИПІ H, Empirical risk figures for first degree relatives of non-insulin dependent diabetics. In Kobberling J and Tattersall R. The Genetics of Diabetes Mellitus. //London: Academic Press — 1982 — s. 201—209.
21. Rich SS., Mapping genes in diabetes. Genetic epidemiological
perspective. // Diabetes - 1990;39[ll] - s.1315-1319. doi: 10.2337/
diab.39.11.1315.
22. Meigs JB, Cuppies LA, Wilson PW, Parental transmission of type 2 diabetes: the Framingham Offspring Study. //Diabetes. - 2000;[49] — s. 2201— 2217.
23. Newman В, Selby JV, King MC, Slemenda C, Fabsitz R, Friedman GD., Concordance for type 2 [non-insulindependent] diabetes mellitus in male twins. - Diabetologia. - 1987;30[10] - s. 763-768. doi: 10.1007/BF00275741.
24. KaprioJ, Tuomilehto J, KoskertvuoM, Romanov K, ReunanenA, Eriksson J, et al. Concordance for Type 1 [insulin-dependent] and Type 2 [non-insulin- dependent] diabetes mellitus in a population-based cohort of twins in Finland. // Diabetologia. - 1992; 35[11] - 5. 1060-1067. doi: 10.1007/BF02221682.
25. Knowler WC, Pettitt DJ, Saad MF, Bennett PH. Diabetes mellitus in the Pima Indians: incidence, risk factors and pathogenesis //Diabetes Metab Rev. - 1990;6[l] - s. 1-27.
26. Grigorescu F, Attaoua R, Ait El Mkadem S, Radian S. Susceptibility genes for insulin resistance and type 2 diabetes. In СЬеюа D [ed]. //Genetics of diabetes. The Truth Unveiled. Ed Acad. Rom, Bucurecti & S. Karger AG, Basel. — 2010 — s. 131—192.
27. Ivanov V.I., Genomika v meditsine. //M: Akademkniga; - 2005 — s. 392
28. Yen CJ, Beamer BA, Negri C, Silver K, Brown KA, Yarnall DP, et al., Molecular scanning of the human Peroxisome proliferator activated receptor g [PPARg] gene in diabetic Caucasians: identification of a Prol2Ala PPARg2 missense mutation. //Biochem Biophys Res Commun. - 1997;241[2] — s. 270-274. doi: 10.1006/bbrc. 1997.7798.
29. Deeb SS, Fajas L, Nemoto M, Pihlajamaki J, Mykkanen L, Kuusisto J, et al. A Prol2Ala substitution in PPARg2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. //Nat Genet. - 1998;20[3] - s. 284—287
30. Altshuler D, Hirschhorn JN, Klannemark M, Lindgren CM, Pohl MC, Nemesh J, et al., The common PPARg Prol2Ala polymorphism is associated with decreased risk of type 2 diabetes. //Nat Genet. - 2000;26[l] — s. 76-80.
31. Robertson R., Beta-cell deterioration during diabetes: what’s in the gun? // Trends Endocrinol Metab. - 2009 Oct;20[8] s.388-93. doi:10.1016/ j. tern. 2009.05.004.
32. Ishonina O.G., Osobennosti metabolicheskikh izmeneniy v krovi patsientok s sakharnym diabetom 2 tipa v zavisimosti ot vozrasta і stepeni kompensatsii uglevodnogo obmena // AVTORYeFYeRAT dissertatsii na soiskanie uchenoy stepeni kandidata biologicheskikh nauk - 2014.
33. Balabolkin M. I., Lechenie sakharnogo diabeta і ego oslozhneniy.:// ucheb. posobie dlya sistemy poslevuz. prof, obrazovaniya vrachey / YeM. Kle¬banova, PM. Kreminskaya. — izdat. Meditsina, - 2005.- s.242 ISBN 5-225-04247-3
34. AM. Pristrom, M Benkhamed, Oksidativnyy stress і serdechno-sosudistye zabolevaniya // Peredovaya statya Lechebnoe delo №1 [23] — 2012g. — s.21-28
35. T.P. Bardymova, L.I. Kolesnikova, M.I. Dolgikh, Perekisnoe okislenie lipidov, antioksidantnaya sistema и bolnykh sakharnym diabetom і faktory vneshney sredy // Byulleten PSNTs SO RAMN, 2006, №1[47].
36. Sukhanova G.A., Serebrov PYu. // Biokhimiya kletki. — Tomsk: Charodey, 2000. - s. 91-142.
37. Kazimirko P.K., Maltsev PI., Antioksidantnaya sistema і ее funktsionirovanie v organizme cheloveka // [Yelektronniy resurs] http: www.health- ua.com — 2004.
38. Issemann II, Green S., Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators //Nature. — 1990 18;347[6294] — s. 645-50.
39. Crabb DW1, Pinaire J, Chou WY, Sissom S, Peters JM, Har¬ris RA, Stewart M., Peroxisome proliferator-activated receptors [PPAR] and the mitochondrial aldehyde dehydrogenase [ALDH2] promoter in vitro and in vivo // Alcohol Clin Exp Res. - 2001 Jul;25[7] - s. 945-52.
40. M.S. Rasin, I.P. Kaydashev, Rol yadernykh transkriptsionnykh faktorov v sintropii sovremennoy vnutrenney patologii [obzor literatury] // Ukrainskiy medichniy chasopis, 1 [99] — I/II 2014 - s. 17-21
41. Giordano Attianese GM1, Desvergne Bl., Integrative and systemic approaches for evaluating PPARe/д [PPARD] function // Nucl Recept Signal. - 2015 Apr 27;13:s. 001. doi: 10.1621/nrs.l3001. eCollection 2015.
42. M. Ricote and С. K. Glass, “PPARs and molecular mechanisms of transrepression, ” //Biochimica et Biophysica Acta Molecular and Cell Biology of Lipids-2007, vol. 1771,№ 8, s. 926-935
43. AM. Rasin, I.P. Kaydashev, M.S. Rasin, Peroksisom proliferator aktiviruyushchie retseptory і ikh rol v sistemnom vospalenii, aterogeneze, arterialnoy gipertenzii і khronicheskom obstruktivnom zabolevanii legkikh // Ukrainskiy terapevtichniy zhurnal — 2006 - № 2, - s. 100-108.
44. Yu S, Reddy JK , Transcription coactivators for peroxisome proliferator- activated receptors // Biochim. Biophys. Acta -2007 - 1771 [8] — s.936- 51. doi: 10.1016/j. bbalip. 2007.01.008.
45. J. Xu and Q. Li, Review of the in vivo functions of the pl 60 steroid receptor coactivator family, //Molecular Endocrinology — 2003 - vol. 17, no. 9, s. 1681—1692
46. M. G. Rosenfeld, V. V. Lunyak, and С. K. Glass, Sensors and signals: a coactivator/corepressor/epigenetic code for integrating signal-dependent programs of transcriptional response // Genes and Development — 2006 - vol. 20, № 11 - s. 1405—1428.
47. Berger J, Moller DE [2002].,The mechanisms of action of PPARs’’. //
Annu. Rev. Med — 2002 53 — s. 409-35. doi:10.1146/annurev.med.53.082901.
104018.
48. Tyagi S, Gupta P, Saini AS, Kaushal C, Sharma S, The peroxisome proliferator-activated receptor: A family of nuclear receptors role in various diseases //JAdv Pharm Technol — 2011 —Res 2 [4] — s. 236—40. doi:10.4103/2231-
4040.90879. PMC 3255347.
49. P. Tontonoz and В. M. Spiegelman, Fat and beyond: the diverse biology of PPARgamma //Annual Review of Biochemistry — 2008 - vol. 77 — s. 289-312
50. A. Vdutsadakis, Peroxisome proliferator-activated receptor у [PPARy] and colorectal carcinogenesis // Journal of Cancer Research and Clinical Oncology - 2007 - vol. 133, Ns 12- s. 917-928
51. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA., An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma [PPAR gamma]. //J Biol Chem - 1995; 270[22] - s. 12953-12956. DOI:http://dx.doi.org/10.1074 jbc.270.22.12953
52. Fonseca VAI., Management of diabetes mellitus and insulin resistance in patients with cardiovascular diseases //Am J Cardiol. - 2003 Aug 18;92[4A] — s. 50J-60J.
53. Asnani SI, Theuma P, Fonseca VA, PPARgamma agonists and vascular risk factors: potential effects on cardiovascular disease // Metab Syndr Relat Disord. - 2003 Mar;l[l] - s. 23-32. doi: 10.1089/154041903321648234.
54. Arunachalam SI, Tirupathi Pichiah PB, Achiraman S., Doxorubicin treatment inhibits PPARz and may induce lipotoxicity by mimicking a type 2 diabetes-like condition in rodent models // FEBS Lett - 2013 Jan 16;587[2] — s. 105-10. doi: 10.1016/j.febslet 2012.11.019.
55. Lin M.H., Chen M.C., Chen Т.Н, Chang H.Y., Chou T.C.., Magnolol ameliorates lipopolysaccharide-induced acute lung injury in rats through PPAR- г-dependent inhibition ofNF-kB activation // Int Immunopharmacol. - 2015 Jun 10;28[l] - s.270-278. doi: 10.1016/j.intimp.2015.05.051
56. Wang XI, Li R., Wang X, Fu Q., Ma S., Umbelliferone ameliorates cerebral ischemia-reperfusion injury via upregulating the PPAR gamma expression and suppressing TXNIP/NLRP3 inflammasome // Neurosci Lett. - 2015 Jul 23;600 - s.182-7. doi: 10.1016/j.neulet.2015.06.016.
57. Sagen JV, Raeder H, HathoutE, ShehadehN, Gudmundsson K, BaevreH, et al., Permanent neonatal diabetes due to mutations in KCNJ11 encoding Kir6.2: patient characteristics and initial response to sulfonylurea therapy. // Diabetes - 2004;53[10] - s. 2713-2718.
58. I. Prokopenko, Type 2 diabetes: new genes, new understandning // Trends Genet. -2008. - Vol. 24[12]. -s. 613-621.
59. Vakhromeeva K.A., Polimorfnye geneticheskie markery sakharnogo diabeta 2-go tipa і ikh assotsiatsii s kliniko- metabolicheskimi pokazatelyami v russkoy populyatsii // Dissertatsiya — 2015
60. Katsura S., Okumura T, Ito R., Sugawara A., Yokoyama A., Identification of Posttranslational Modifications in Peroxisome Proliferator-Activated Receptor г Using Mass Spectrometry // PPAR Res. - 2014 - s.468-925. doi: 10.1155/ 2014/468925.
61. Meirhaeghe A, Amouyel P, “Impact of genetic variation of PPARgamma in humans”.//Mol. Genet. Metab. — 2004 — 83 [1-2] — s. 93—102. doi:10.1016/ j.ymgme.2004.08.014.
62. Z. E. Floyd and J. M. Stephens, Controlling a master switch of adipocyte development and insulin sensitivity: covalent modifications of PPARz // Biochimica et Biophysica Acta. Molecular Basis of Disease — 2012 - vol. 1822, № 7 — s. 1090-1095
63. Davies NA, Watkeys L, Butcher L, Potter S, HughesM.G., Moir H, Morris K, Thomas A. W., Webb R, The contributions of oxidative stress, oxidised lipoproteins and AMPK towards exercise-associated PPARz signalling within human monocytic cells. //Free Radio Res. — 2015 - Jan;49[l] — s.45-56. doi: 10.3109/10715762.2014.978311.
64. Herder C, Rathmann W, Strassburger K, Finner H, Grallert H, Huth C, Meisinger C, Gieger C, Martin S, Giani G, Scherbaum WA, Wichmann HE, Illig T, Variants of the PPARG, IGF2BP2, CDKAL1, HHEX, and TCF7L2 genes confer risk of type 2 diabetes independently ofBMI in the German //KORA studies. — 2008 - 40[l0] - s.722-726.
65. Hebe N. Gouda, Gurdeep S. Sagoo, Anne-Helen Harding, Jan Yates, Manjinder S. Sandhu, and Julian P. T. Higgins, The Association Between the Peroxisome Proliferator-Activated Receptor-z2 [PPARG2] Prol2Ala Gene Variant and Type 2 Diabetes Mellitus: A HuGE Review and Meta-Analysis // Am J Epidemiol. -2010- Mar 15; 171 [6] - s. 645-655
66. Buzzetti R, Petrone A, RibaudoM.C, Alemanno I, Zavarella S, Mein C.A., Maiani F, Tiberti C., Baroni M.G., Vecci E., ArcaM., Leonetti F, Di Mario U, The common PPAR-gamma2 Prol2Ala variant is associated with greater insulin sensitivity // European Journal of Human Genetics — 2004 - 12[ 12] — S.1050-A. doi: 10.1038/sj. ejhg. 5201283.
67. Sanghera D.K., Demirci F.Y., Been L., Ortega L, Ralhan S, Wander G.S., MehraN.K., Singh J, Aston C.E., Mulvihill J. J., Kamboh I.M., PPARG and ADIPOQ
2. World Health Organization. Global Health Estimates: Deaths by Cause, Age, Sex and Country, 2000 — 2012. Geneva // WHO — 2014.
3. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 203 0. // PLoS Med - 2006, -3[ll]-s. 442.
4. Diabet — informatsionnyy byulleten VOZ №312, yanvar, 2015 g. [http:// www.who.int/mediacentre/factsheets/fs312/ru/]
5. Hu FB. Globalization of Diabetes: The role of diet, lifestyle, and genes. Diabetes Care — 2011;34[6] — s. 1249-1257. [Yelektronniy resurs].— Rezhim dostupu do resursu: http://dxdoi.org/10.2337/dcll-0442
6. Mayer-Davis EJ. Type 2 diabetes in youth: epidemiology and current research toward prevention and treatment //J. Am. Diet Assoc. — 2008. — Vol. 108, № 4 [Suppl 1]. - S.S45-S51.
7. Zhurakivska O.Ya., Titik W, Zhurakivska V.M., Pertsovich V.M., Rol protsesiv perokisnogo okislennya lipidiv и rozvitku diabetichnikh mikroangiopatiy // Zdobutki klinichnoi і eksperimentalnol meditsini — 2014 — № 12-S.232
8. Osnovni pokazniki diyalnosti endokrinologichnol sluzhbi Ukralni za 2003 rik [dovidnik], — Kilv, 2004. — s. 23.
9. Dovidnik osnovnikh pokaznikiv diyalnosti endokrinologichnol sluzhbi Ukralni za 2003 rik // Yendokrinologiya. — 2014. — T. 19, №1, dodatok 1. — s. 40
10. Tkachenko VI., k. med. n., dotsent, Analiz poshirenosti ta zakhvoryuvanosti na TsD sered naselennya svitu ta Ukralni za 2003—2013 rr. //Liki Ukralni -2014- №4 [21] - s. 55-59.
11. ZimmetP., Abstract Book The 2nd Xenical Event Monte Carlo, March 14— 16, 2003.
12. Butrova S.A., Ot epidemii ozhireniya k epidemii sakharnogo diabeta // Mezhdunarodnyy endokrinologicheskiy zhurnal — 2013 - № 2[50] — s. 19-23, ISSN 2224-0721.
13. Suplotova L.A., 2 Belchikova L.N., 2 Rozhnova N. A. Epidemiologicheskie aspekty sakharnogo diabeta 2 tipa s manifestatsiey zabolevaniya v molodom vozraste Epidemiologiya // Sakharnyy diabet. - 2012;[1]: - s. 11—13.
14. ZimmetP, Alberti K. et al. //Nature. - 2001. — 414. S. 782-7.
15. Dedova I.I., Algoritmy spetsializirovannoy meditsinskoy pomoshchi bol- nym sakharnym diabetom. [6-у vypusk]. //Sakharnyy diabet. —2013 - [Is] — s.1—120.
16. Baranov VS, Glotov AS, Ivashchenko ТЕ. Geneticheskiy pasport — osnova individualnoy і prediktivnoy meditsiny. // Sankt-Peterburg: Izdatelstvo N-L; - 2009.
17. Klyueva S.K, Multifaktorialnye zabolevaniya. // SPb.: SPb. МАРО - 2002. — s. 144
18. Dedov I.I., Smirnova O.M., Kononenko I.V.,Znachenie rezultatov polnogenomnykh issledovaniy dlya pervichnoy profilaktiki sakharnogo diabeta 2 tipa і ego oslozhneniy. Personalizirovannyy podkhod // Sakharnyy diabet. - 2014;[2] - s. 10-19
19. Bondar I.A., Shabelnikova O.Yu. Geneticheskie osnovy sakharnogo diabeta 2 tipa //Sakharnyy diabet. - 2013;[4] — s.11—16
20. Kobberling J, ТИПІ H, Empirical risk figures for first degree relatives of non-insulin dependent diabetics. In Kobberling J and Tattersall R. The Genetics of Diabetes Mellitus. //London: Academic Press — 1982 — s. 201—209.
21. Rich SS., Mapping genes in diabetes. Genetic epidemiological
perspective. // Diabetes - 1990;39[ll] - s.1315-1319. doi: 10.2337/
diab.39.11.1315.
22. Meigs JB, Cuppies LA, Wilson PW, Parental transmission of type 2 diabetes: the Framingham Offspring Study. //Diabetes. - 2000;[49] — s. 2201— 2217.
23. Newman В, Selby JV, King MC, Slemenda C, Fabsitz R, Friedman GD., Concordance for type 2 [non-insulindependent] diabetes mellitus in male twins. - Diabetologia. - 1987;30[10] - s. 763-768. doi: 10.1007/BF00275741.
24. KaprioJ, Tuomilehto J, KoskertvuoM, Romanov K, ReunanenA, Eriksson J, et al. Concordance for Type 1 [insulin-dependent] and Type 2 [non-insulin- dependent] diabetes mellitus in a population-based cohort of twins in Finland. // Diabetologia. - 1992; 35[11] - 5. 1060-1067. doi: 10.1007/BF02221682.
25. Knowler WC, Pettitt DJ, Saad MF, Bennett PH. Diabetes mellitus in the Pima Indians: incidence, risk factors and pathogenesis //Diabetes Metab Rev. - 1990;6[l] - s. 1-27.
26. Grigorescu F, Attaoua R, Ait El Mkadem S, Radian S. Susceptibility genes for insulin resistance and type 2 diabetes. In СЬеюа D [ed]. //Genetics of diabetes. The Truth Unveiled. Ed Acad. Rom, Bucurecti & S. Karger AG, Basel. — 2010 — s. 131—192.
27. Ivanov V.I., Genomika v meditsine. //M: Akademkniga; - 2005 — s. 392
28. Yen CJ, Beamer BA, Negri C, Silver K, Brown KA, Yarnall DP, et al., Molecular scanning of the human Peroxisome proliferator activated receptor g [PPARg] gene in diabetic Caucasians: identification of a Prol2Ala PPARg2 missense mutation. //Biochem Biophys Res Commun. - 1997;241[2] — s. 270-274. doi: 10.1006/bbrc. 1997.7798.
29. Deeb SS, Fajas L, Nemoto M, Pihlajamaki J, Mykkanen L, Kuusisto J, et al. A Prol2Ala substitution in PPARg2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. //Nat Genet. - 1998;20[3] - s. 284—287
30. Altshuler D, Hirschhorn JN, Klannemark M, Lindgren CM, Pohl MC, Nemesh J, et al., The common PPARg Prol2Ala polymorphism is associated with decreased risk of type 2 diabetes. //Nat Genet. - 2000;26[l] — s. 76-80.
31. Robertson R., Beta-cell deterioration during diabetes: what’s in the gun? // Trends Endocrinol Metab. - 2009 Oct;20[8] s.388-93. doi:10.1016/ j. tern. 2009.05.004.
32. Ishonina O.G., Osobennosti metabolicheskikh izmeneniy v krovi patsientok s sakharnym diabetom 2 tipa v zavisimosti ot vozrasta і stepeni kompensatsii uglevodnogo obmena // AVTORYeFYeRAT dissertatsii na soiskanie uchenoy stepeni kandidata biologicheskikh nauk - 2014.
33. Balabolkin M. I., Lechenie sakharnogo diabeta і ego oslozhneniy.:// ucheb. posobie dlya sistemy poslevuz. prof, obrazovaniya vrachey / YeM. Kle¬banova, PM. Kreminskaya. — izdat. Meditsina, - 2005.- s.242 ISBN 5-225-04247-3
34. AM. Pristrom, M Benkhamed, Oksidativnyy stress і serdechno-sosudistye zabolevaniya // Peredovaya statya Lechebnoe delo №1 [23] — 2012g. — s.21-28
35. T.P. Bardymova, L.I. Kolesnikova, M.I. Dolgikh, Perekisnoe okislenie lipidov, antioksidantnaya sistema и bolnykh sakharnym diabetom і faktory vneshney sredy // Byulleten PSNTs SO RAMN, 2006, №1[47].
36. Sukhanova G.A., Serebrov PYu. // Biokhimiya kletki. — Tomsk: Charodey, 2000. - s. 91-142.
37. Kazimirko P.K., Maltsev PI., Antioksidantnaya sistema і ее funktsionirovanie v organizme cheloveka // [Yelektronniy resurs] http: www.health- ua.com — 2004.
38. Issemann II, Green S., Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators //Nature. — 1990 18;347[6294] — s. 645-50.
39. Crabb DW1, Pinaire J, Chou WY, Sissom S, Peters JM, Har¬ris RA, Stewart M., Peroxisome proliferator-activated receptors [PPAR] and the mitochondrial aldehyde dehydrogenase [ALDH2] promoter in vitro and in vivo // Alcohol Clin Exp Res. - 2001 Jul;25[7] - s. 945-52.
40. M.S. Rasin, I.P. Kaydashev, Rol yadernykh transkriptsionnykh faktorov v sintropii sovremennoy vnutrenney patologii [obzor literatury] // Ukrainskiy medichniy chasopis, 1 [99] — I/II 2014 - s. 17-21
41. Giordano Attianese GM1, Desvergne Bl., Integrative and systemic approaches for evaluating PPARe/д [PPARD] function // Nucl Recept Signal. - 2015 Apr 27;13:s. 001. doi: 10.1621/nrs.l3001. eCollection 2015.
42. M. Ricote and С. K. Glass, “PPARs and molecular mechanisms of transrepression, ” //Biochimica et Biophysica Acta Molecular and Cell Biology of Lipids-2007, vol. 1771,№ 8, s. 926-935
43. AM. Rasin, I.P. Kaydashev, M.S. Rasin, Peroksisom proliferator aktiviruyushchie retseptory і ikh rol v sistemnom vospalenii, aterogeneze, arterialnoy gipertenzii і khronicheskom obstruktivnom zabolevanii legkikh // Ukrainskiy terapevtichniy zhurnal — 2006 - № 2, - s. 100-108.
44. Yu S, Reddy JK , Transcription coactivators for peroxisome proliferator- activated receptors // Biochim. Biophys. Acta -2007 - 1771 [8] — s.936- 51. doi: 10.1016/j. bbalip. 2007.01.008.
45. J. Xu and Q. Li, Review of the in vivo functions of the pl 60 steroid receptor coactivator family, //Molecular Endocrinology — 2003 - vol. 17, no. 9, s. 1681—1692
46. M. G. Rosenfeld, V. V. Lunyak, and С. K. Glass, Sensors and signals: a coactivator/corepressor/epigenetic code for integrating signal-dependent programs of transcriptional response // Genes and Development — 2006 - vol. 20, № 11 - s. 1405—1428.
47. Berger J, Moller DE [2002].,The mechanisms of action of PPARs’’. //
Annu. Rev. Med — 2002 53 — s. 409-35. doi:10.1146/annurev.med.53.082901.
104018.
48. Tyagi S, Gupta P, Saini AS, Kaushal C, Sharma S, The peroxisome proliferator-activated receptor: A family of nuclear receptors role in various diseases //JAdv Pharm Technol — 2011 —Res 2 [4] — s. 236—40. doi:10.4103/2231-
4040.90879. PMC 3255347.
49. P. Tontonoz and В. M. Spiegelman, Fat and beyond: the diverse biology of PPARgamma //Annual Review of Biochemistry — 2008 - vol. 77 — s. 289-312
50. A. Vdutsadakis, Peroxisome proliferator-activated receptor у [PPARy] and colorectal carcinogenesis // Journal of Cancer Research and Clinical Oncology - 2007 - vol. 133, Ns 12- s. 917-928
51. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA., An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma [PPAR gamma]. //J Biol Chem - 1995; 270[22] - s. 12953-12956. DOI:http://dx.doi.org/10.1074 jbc.270.22.12953
52. Fonseca VAI., Management of diabetes mellitus and insulin resistance in patients with cardiovascular diseases //Am J Cardiol. - 2003 Aug 18;92[4A] — s. 50J-60J.
53. Asnani SI, Theuma P, Fonseca VA, PPARgamma agonists and vascular risk factors: potential effects on cardiovascular disease // Metab Syndr Relat Disord. - 2003 Mar;l[l] - s. 23-32. doi: 10.1089/154041903321648234.
54. Arunachalam SI, Tirupathi Pichiah PB, Achiraman S., Doxorubicin treatment inhibits PPARz and may induce lipotoxicity by mimicking a type 2 diabetes-like condition in rodent models // FEBS Lett - 2013 Jan 16;587[2] — s. 105-10. doi: 10.1016/j.febslet 2012.11.019.
55. Lin M.H., Chen M.C., Chen Т.Н, Chang H.Y., Chou T.C.., Magnolol ameliorates lipopolysaccharide-induced acute lung injury in rats through PPAR- г-dependent inhibition ofNF-kB activation // Int Immunopharmacol. - 2015 Jun 10;28[l] - s.270-278. doi: 10.1016/j.intimp.2015.05.051
56. Wang XI, Li R., Wang X, Fu Q., Ma S., Umbelliferone ameliorates cerebral ischemia-reperfusion injury via upregulating the PPAR gamma expression and suppressing TXNIP/NLRP3 inflammasome // Neurosci Lett. - 2015 Jul 23;600 - s.182-7. doi: 10.1016/j.neulet.2015.06.016.
57. Sagen JV, Raeder H, HathoutE, ShehadehN, Gudmundsson K, BaevreH, et al., Permanent neonatal diabetes due to mutations in KCNJ11 encoding Kir6.2: patient characteristics and initial response to sulfonylurea therapy. // Diabetes - 2004;53[10] - s. 2713-2718.
58. I. Prokopenko, Type 2 diabetes: new genes, new understandning // Trends Genet. -2008. - Vol. 24[12]. -s. 613-621.
59. Vakhromeeva K.A., Polimorfnye geneticheskie markery sakharnogo diabeta 2-go tipa і ikh assotsiatsii s kliniko- metabolicheskimi pokazatelyami v russkoy populyatsii // Dissertatsiya — 2015
60. Katsura S., Okumura T, Ito R., Sugawara A., Yokoyama A., Identification of Posttranslational Modifications in Peroxisome Proliferator-Activated Receptor г Using Mass Spectrometry // PPAR Res. - 2014 - s.468-925. doi: 10.1155/ 2014/468925.
61. Meirhaeghe A, Amouyel P, “Impact of genetic variation of PPARgamma in humans”.//Mol. Genet. Metab. — 2004 — 83 [1-2] — s. 93—102. doi:10.1016/ j.ymgme.2004.08.014.
62. Z. E. Floyd and J. M. Stephens, Controlling a master switch of adipocyte development and insulin sensitivity: covalent modifications of PPARz // Biochimica et Biophysica Acta. Molecular Basis of Disease — 2012 - vol. 1822, № 7 — s. 1090-1095
63. Davies NA, Watkeys L, Butcher L, Potter S, HughesM.G., Moir H, Morris K, Thomas A. W., Webb R, The contributions of oxidative stress, oxidised lipoproteins and AMPK towards exercise-associated PPARz signalling within human monocytic cells. //Free Radio Res. — 2015 - Jan;49[l] — s.45-56. doi: 10.3109/10715762.2014.978311.
64. Herder C, Rathmann W, Strassburger K, Finner H, Grallert H, Huth C, Meisinger C, Gieger C, Martin S, Giani G, Scherbaum WA, Wichmann HE, Illig T, Variants of the PPARG, IGF2BP2, CDKAL1, HHEX, and TCF7L2 genes confer risk of type 2 diabetes independently ofBMI in the German //KORA studies. — 2008 - 40[l0] - s.722-726.
65. Hebe N. Gouda, Gurdeep S. Sagoo, Anne-Helen Harding, Jan Yates, Manjinder S. Sandhu, and Julian P. T. Higgins, The Association Between the Peroxisome Proliferator-Activated Receptor-z2 [PPARG2] Prol2Ala Gene Variant and Type 2 Diabetes Mellitus: A HuGE Review and Meta-Analysis // Am J Epidemiol. -2010- Mar 15; 171 [6] - s. 645-655
66. Buzzetti R, Petrone A, RibaudoM.C, Alemanno I, Zavarella S, Mein C.A., Maiani F, Tiberti C., Baroni M.G., Vecci E., ArcaM., Leonetti F, Di Mario U, The common PPAR-gamma2 Prol2Ala variant is associated with greater insulin sensitivity // European Journal of Human Genetics — 2004 - 12[ 12] — S.1050-A. doi: 10.1038/sj. ejhg. 5201283.
67. Sanghera D.K., Demirci F.Y., Been L., Ortega L, Ralhan S, Wander G.S., MehraN.K., Singh J, Aston C.E., Mulvihill J. J., Kamboh I.M., PPARG and ADIPOQ
Як цитувати
Мокрий, В. (1). РОЛЬ ГЕНА РЕЦЕПТОРА АКТИВАТОРА ПЕРОКСИСОМ ПРИ ЦУКРОВОМУ ДІАБЕТІ II ТИПУ. Український науково-медичний молодіжний журнал, 4(91), 17-26. вилучено із https://mmj.nmuofficial.com/index.php/journal/article/view/184
Розділ
ТЕОРЕТИЧНА МЕДИЦИНА
